DaVita Inc.
DVA
주식 순위
#1799
DaVita Inc. specializes in delivering essential kidney dialysis treatments and... DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
주가
$186.81
마지막 동기화: 2026-10-16
시가총액
$11.92B
변동 (1일)
-1.10%
변동 (1년)
48.40%
국가
US
거래 DaVita Inc. (DVA)
카테고리
Healthcare
DaVita Inc. (DVA)의 영업이익률
October 2026 기준 영업이익률 TTM: 15.06%
DaVita Inc.의 최신 재무 보고서와 주가에 따르면 현재 영업이익률 (TTM)은 15.06%입니다. 2024년 말 기준 영업이익률은 16.31%였습니다.
DaVita Inc.의 영업이익률 기록 (2000 ~ 2026)
매년 말 영업이익률
| 연도 | 영업이익률 | 변화 |
|---|---|---|
| 2026 (TTM) | 15.06% | 4.95% |
| 2025 | 14.35% | -12.02% |
| 2024 | 16.31% | 23.56% |
| 2023 | 13.20% | 14.48% |
| 2022 | 11.53% | -25.47% |
| 2021 | 15.47% | 5.45% |
| 2020 | 14.67% | 1.66% |
| 2019 | 14.43% | 7.85% |
| 2018 | 13.38% | -19.74% |
| 2017 | 16.67% | 21.06% |
| 2016 | 13.77% | 66.91% |
| 2015 | 8.25% | -41.86% |
| 2014 | 14.19% | 7.66% |
| 2013 | 13.18% | -16.79% |
| 2012 | 15.84% | -6.82% |
| 2011 | 17.00% | 10.32% |
| 2010 | 15.41% | 0.13% |
| 2009 | 15.39% | 0.26% |
| 2008 | 15.35% | -6.29% |
| 2007 | 16.38% | 8.12% |
| 2006 | 15.15% | -3.19% |
| 2005 | 15.65% | -5.61% |
| 2004 | 16.58% | -5.74% |
| 2003 | 17.59% | -15.02% |
| 2002 | 20.70% | 9.93% |
| 2001 | 18.83% | 56.14% |
| 2000 | 12.06% | 0.00% |
유사 기업 또는 경쟁사의 영업이익률
| 회사 | 영업이익률 | 영업이익률 차이 | 국가 |
|---|---|---|---|
| 15.48% | -98.97% |
US
|
|
| 0.00% | - |
DE
|
|
| 16.80% | -98.88% |
US
|
|
| 18.67% | -98.76% |
SA
|
|
| 0.00% | - |
MY
|
회사의 영업이익률이란?
영업이익률은 회사의 수익성을 평가하는 핵심 지표입니다. 높은 영업이익률은 일반적으로 긍정적으로 간주되며, 이는 회사가 제품이나 서비스를 생산 비용보다 훨씬 높은 가격에 판매할 수 있음을 보여줍니다. 영업이익률은 회사의 수익을 매출로 나누어 계산합니다.